Galena Biopharma is a biopharmaceutical company focused on developing and commercializing treatments to address major unmet medical needs in the field of oncology. As GALE works to expand its drug candidate portfolio, the company’s stated mission is to accelerate value for both patients and company shareholders, a goal that requires support and guidance from an experienced and aggressive management team.
Leading the company’s corporate initiatives is Mark J. Ahn, Ph.D., who has more than 20 years of experience in the biopharmaceutical industry. Dr. Ahn has served as GALE’s president and CEO since March 2011, and has also served as a director of the company since 2007.
Prior to joining GALE, Dr. Ahn was principal at Pukana Partners, Ltd., which provides strategic consulting to life science companies; and associate professor of Global Management at Atkinson Graduate School of Management, Willamette University. He also previously served as professor and chair of Science & Technology Management for Victoria University at Wellington, New Zealand.
Dr. Ahn was also founder and was previously the president and CEO of Hana Biosciences following his employment as vice president of Hematology and corporate officer at Genentech, Inc. In addition, he has held positions of increasing responsibility at Amgen (AMGN) and Bristol-Myers Squibb (BMY).
Dr. Ahn has authored more than 50 peer reviewed journal articles and books, and serves on public and venture capital-backed board of directors for Access Pharmaceuticals, Mesynthes, and ScribesSTAT. He received a BA and an MBA from Chaminade University, as well as an MA from Victoria University. Furthermore, Dr. Ahn was a graduate fellow in economics at Essex University, and obtained a Ph.D. from the University of South Australia. Dr. Ahn is a Henry Crown Fellow at the Aspen Institute.
For more information visit www.galenabiopharma.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
